Education
About Us
Working with TipRanks
Follow Us
Pharvaris (PHVS)
NASDAQ:PHVS
PHVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.76 - $25.50
Previous CloseN/A
Volume14.65K
Average Volume (3M)40.48K
Market Cap
$670.27M
Enterprise Value$751.34M
Total Cash (Recent Filing)€1.35M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.11
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.69
Shares Outstanding54,493,140
10 Day Avg. Volume28,969
30 Day Avg. Volume40,481
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$34.33Price Target Upside190.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Pharvaris News
PremiumCompany Announcements
Pharvaris Reports 2024 Financial Results and Business Progress
PremiumCompany Announcements
Pharvaris Reports 2024 Financial Results and Advances HAE Treatment Studies---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe pivotal trial testing deucrictibant for the on-demand treatment of HAE attacks has achieved target enrollment, strengthening confidence in clinical timelines.
Market PositionPharvaris is expected to offer the only oral option for both prevention and treatment of HAE attacks, potentially expanding its market.
Product EfficacyDeucrictibant appears competitive vs sebetralstat, as it reduced attack symptoms by 50% in approximately 4 hours compared to 6 hours in sebetralstat, and 86% of patients reached attack resolution on deucrictibant at 24-hours compared to 44-52% on sebetralstat.
Bears Say
CompetitionDespite the entrenched competition in HAE, deucrictibant's differentiated profile could drive blockbuster sales.
Financial PerformancePHVS had a net loss of $36M for the quarter, which was below consensus expectations.
---
Ownership Overview
―
Insiders
8.00% Mutual Funds
68.91% Other Institutional Investors
22.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PHVS FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was $11.76 and its highest was $25.50 in the past 12 months.
What is Pharvaris’s market cap?
Pharvaris’s market cap is $670.27M.
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is May 07, 2025 which is in 26 days.
How were Pharvaris’s earnings last quarter?
Pharvaris released its earnings results on Apr 07, 2025. The company reported -$0.702 earnings per share for the quarter, beating the consensus estimate of -$0.89 by $0.188.
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharvaris have?
Pharvaris has 54,493,140 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Pharvaris reported an EPS of -$0.702 in its last earnings report, beating expectations of -$0.89. Following the earnings report the stock price went down -7.493%.
Which hedge fund is a major shareholder of Pharvaris?
Currently, no hedge funds are holding shares in PHVS
---
Pharvaris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.33 (190.19% Upside)
$34.33 (190.19% Upside)
Hedge Fund Trend
Increased
By 30.3K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.84%
12-Months-Change
Fundamentals
Return on Equity
-41.43%
Trailing 12-Months
Asset Growth
-31.49%
Trailing 12-Months
Company Description
Pharvaris
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
---
PHVS Stock 12 Month Forecast
Average Price Target
$34.33
▲(190.19% Upside)
Technical Analysis
Eloxx Pharmaceuticals
―
AnaptysBio
―
Kiniksa Pharmaceuticals
―
Akero Therapeutics
―
Arcutis Biotherapeutics
―
Best Analysts Covering PHVS
1 Year
1 Year Success Rate
10/24 ratings generated profit
1 Year Average Return
+40.30%
reiterated a buy rating 4 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +40.30% per trade.
---